INDERAL

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Germany, Japan, Malta, South Africa.

Active ingredients

The drug INDERAL contains one active pharmaceutical ingredient (API):

1	Propranolol UNII F8A3652H1V - PROPRANOLOL HYDROCHLORIDE
	Propranolol is a competitive antagonist at both beta, and beta2-adrenoceptor, but has membrane stabilising activity at concentrations exceeding 1-3mg/litre, though such concentrations are rarely achieved during oral therapy. Competitive beta-blockade has been demonstrated in man by a parallel shift to the right in the dose-heart rate response curve to beta-agonists such as isoprenaline.
	Read more about Propranolol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INDERAL Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C07AA05	Propranolol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AA Beta blocking agents, non-selective
Discover more medicines within C07AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2565B, 2566C
CA	Health Products and Food Branch	02042231, 02042258, 02042266, 02042274
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	01208381
JP	医薬品医療機器総合機構	2123008F1048, 2123402A1020
MT	Medicines Authority	AA565/52801
US	FDA, National Drug Code	62559-520, 62559-521, 62559-522, 62559-523, 62559-600, 62559-601
ZA	Health Products Regulatory Authority	G/5.2/2863, M/5.2/127, S/5.2/199